

# Cancer Immunology Immunotherapy

Founding Editor  
G. Mathé

Other Biological Response Modifications

Volume 26 1988

## Editors in Chief

R. W. Baldwin E. Mihich

## Editorial Board

R. Arnon Rehovot  
R. Bast Durham, NC  
S. Ben-Efraim Tel Aviv  
J. Bennett Albany, NY  
N. Bloksma Utrecht  
T. Boon Brussels  
E. C. Borden Madison, WI  
V. S. Byers Berkeley, CA  
T. Carey Ann Arbor, MI  
M. Cheever Seattle, WA  
M. Colnaghi Milan  
W. Den Otter Utrecht  
S. Dray Chicago, IL  
S. Eccles Sutton, Surrey

I. Fidler Houston, TX  
E. Grimm Houston, TX  
K. Hellström Seattle, WA  
J. Kieler Copenhagen  
H. Kirchner Heidelberg  
H. Kobayashi Sapporo  
M. Mastrangelo Philadelphia, PA  
J. McVie Amsterdam  
M. Micksche Vienna  
M. Mitchell Los Angeles, CA  
R. J. North Saranac Lake, NY  
G. Parmiani Milan  
H. M. Pinedo Amsterdam  
T. J. Priestman Birmingham

R. Rees Sheffield  
P. Rümke Amsterdam  
D. Scott Rochester, NY  
K. Sikora London  
Z. Steplewski Philadelphia, PA  
G. Stevenson Southampton  
J. Talmadge King of Prussia, PA  
E. Tsubura Osaka  
A. Uchida Kyoto  
F. Vánky Stockholm  
E. Vitetta Dallas, TX  
B. Vose Cheshire  
Y. Yamamura Osaka



Springer International

# Cancer Immunology Immunotherapy

## Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé

Editors: R. W. Baldwin, E. Mihich

Published by Springer International

### Copyright

*Submission of a manuscript implies:* that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e.g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

*Special regulations for photocopies in the USA:* Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U.S. Copyright Law, provided a fee is paid. This fee is US \$ 0.20 per page, or a minimum of US \$ 1.00 if an article contains fewer than five pages. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1988

## Contents of volume 26

No. 1 (pp 1-94) published February 11, 1988  
No. 2 (pp 95-186) published March 28, 1988  
No. 3 (pp 187-284) published June 8, 1988

Abdallah RM → Meadows GG, et al. 67  
Aguado MT → Buikh A, et al. 280  
Asher A → Mulé JJ, et al. 202  
Aslakson CJ → Meadows GG, et al. 67  
Awad M, North RJ: Sublethal, whole-body ionizing irradiation can be tumor promotive or tumor destructive depending on the stage of development of underlying antitumor immunity 55

Bakker WH → Berends D, et al. 243  
Ballatori E → Liberati AM, et al. 87  
Barbieri L → Tazzari PL, et al. 231  
Barrett J → Wahl RL, et al. 187  
Ben-Efraim S → Reuben C, et al. 153  
Berends D, Gaalen JLM van, Rhijnburger EH, Both NJ de, Breeman W, Bakker WH, Kooy P: The detection of virally induced tumors by <sup>131</sup>I- and <sup>125</sup>I-labeled syngeneic monoclonal antibodies 243

Bjorn MJ, Smith HS, Dairkee SH: Response of primary human mammary tumor cell cultures to a monoclonal antibody-recombinant ricin A chain immunotoxin 121

Bontadini A → Tazzari PL, et al. 231  
Both NJ de → Berends D, et al. 243  
Bourel D → Collet B, et al. 237  
Breeman W → Berends D, et al. 243  
Bryson JS, Cox DC: Characteristics of reovirus-mediated chemotherapy of murine L1210 leukemia 132

Bukh A, Möller-Larsen A, Aguado MT, Möller-Larsen F, Möller NPH: Prognostic value of serial determinations of circulating immune complex levels in malignant melanoma 280

Canevari S → Orlandi R, et al. 114  
Cinieri S → Liberati AM, et al. 87  
Cini L → Liberati AM, et al. 87  
Clemente C → Taramelli D, et al. 61  
Collet B, Pellen P, Martin A, Moisan A, Bourel D, Toujas L: Scintigraphic detection in mice of inflammatory lesions and tumours by an indium-labelled monoclonal antibody directed against Mac-1 antigen 237

Colnaghi MI → Orlandi R, et al. 114  
Conde FP → Orlandi R, et al. 114  
Cox DC → Bryson JS 132

Dairkee SH → Bjorn MJ, et al. 121  
Dalen A → Helseth E, et al. 273  
Den Otter W → Los G, et al. 145  
De Weger RA → Los G, et al. 145  
Di Marzio R → Liberati AM, et al. 87  
Dinota A → Tazzari PL, et al. 231  
Duffy TM → Evans R, et al. 35

Eggermont AMM, Sugerbaker PH, Marquet RL, Jeekel J: In vivo generation of lymphokine activated killer cell activity by ABPP and interleukin-2 and their antitumor effects against immunogenic and nonimmunogenic tumors in murine tumor models 23

Ershler WB → Hadar EJ, et al. 31  
Evans R, Duffy TM, Shultz LD: The immunological mouse mutants nude (*nu*) and rhino (*hr*<sup>m</sup>) generate cytotoxic effector cells following adoptive immunotherapy but fail to reject a transplanted tumor 35

Fady C → Pelletier H, et al. 263  
Fazioli F → Romani L, et al. 48  
Fioretti MC → Romani L, et al. 48

Fisher S → Wahl RL, et al. 187  
Fizzotti M → Liberati AM, et al. 87  
Fossati G → Taramelli D, et al. 61  
Fuchs C, Krapf F, Kern P, Hoferichter S, Jäger W, Kalden JR: CEA-containing immune complexes in sera of patients with colorectal and breast cancer. Analysis of complexed immunoglobulin classes 180

Fujiwara H → Shima J, et al. 43

Gaalen JLM van → Berends D, et al. 243  
Geatti O → Wahl RL, et al. 187  
Gobbi M → Tazzari PL, et al. 231  
Goepel JR → Wing MG, et al. 161  
Golub SH → Ramsdell FJ, et al. 139  
Greiner JW → Guadagni F, et al. 222  
Grignani F → Liberati AM, et al. 87  
Grohmann U → Romani L, et al. 48

Grossman HB, Wedemeyer G, Stein J: Autologous antibodies to human bladder cancer 269

Guadagni F, Schliom J, Pothen S, Pestka S, Greiner JW: Parameters involved in the enhancement of monoclonal antibody targeting in vivo with recombinant interferon 222

Hadar EJ, Ershler WB, Kreisle RA, Ho S-P, Volk MJ, Klopp RG: Lymphocyte-induced angiogenesis factor is produced by L3T4<sup>+</sup> murine T lymphocytes, and its production declines with age 31

Halperin D → Reuben C, et al. 153  
Hamada J → Morikawa K, et al. 18  
Hamaoka T → Shima J, et al. 43  
Hank JA → Kohler PC, et al. 74

Helseth E, Unsøgaard G, Dalen A, Vik R: Effects of type beta transforming growth factor in combination with retinoic acid or tumor necrosis factor on proliferation of a human glioblastoma cell line and clonogenic cells from freshly resected human brain tumors 273

Heo DS → Whiteside TL, et al. 1

Heppner GH → Wei W-Z 257

Herberman RB → Whiteside TL, et al. 1

Higuchi M → Shimoda O, et al. 101  
Hoferichter S → Fuchs C, et al. 180

Hosoe S → Yokota S, et al. 11

Hosokawa M → Morikawa K, et al. 18

Hosokawa M, Sawamura Y, Morikage T, Okada F, Xu Z-Y, Morikawa K, Zoh K, Kobayashi H: Improved therapeutic effects of interleukin 2 after the accumulation of lymphokine-activated killer cells in tumor tissue of mice previously treated with cyclophosphamide 250

Ho S-P → Hadar EJ, et al. 31

Iigo M → Sakurai M, et al. 109  
Ikeda T → Yokota S, et al. 11  
Ishikawa M → Morikawa K, et al. 18

Itaya T → Morikawa K, et al. 18  
Itoh K → Hosokawa M, et al. 250

Iwatsuki S → Whiteside TL, et al. 1

Jacob G → Wing MG, et al. 161  
Jacob G → Wing MG, et al. 169  
Jäger W → Fuchs C, et al. 180  
Jeannin J-F → Pelletier H, et al. 263

Jeekel J → Eggermont AMM, et al. 23

Johnson JT → Whiteside TL, et al. 1

Kalden JR → Fuchs C, et al. 180

Kato I, Yokokura T, Mutai M: Correlation between increase in lab-bearing macrophages and induction of T cell-dependent antitumor activity by *Lactobacillus casei* in mice 215

Kawase I → Yokota S, et al. 11  
 Kern P → Fuchs C, et al. 180  
 Kieler J → Ottesen SS, et al. 83  
 Kishimoto S → Yokota S, et al. 11  
 Klopp RG → Hadar EJ, et al. 31  
 Kobayashi H → Morikawa K, et al. 18  
 Kobayashi H → Hosokawa M, et al. 250  
 Kohler PC, Hank JA, Minkoff DZ, Sondel PM: Clinical adoptive chemoimmunotherapy with allogeneic alloactivated HLA-haploidentical lymphocytes: controlled induction of graft-versus-host-reactions 74  
 Komuta K → Yokota S, et al. 11  
 Kooy P → Berends D, et al. 243  
 Krapf F → Fuchs C, et al. 180  
 Kreisle RA → Hadar EJ, et al. 31  
 Lafreniere R → Mulé JJ, et al. 202  
 Lagadec P → Pelletier H, et al. 263  
 Lefor A → Mulé JJ, et al. 202  
 Leoni F → Orlandi R, et al. 114  
 Levy JG → Steele JK, et al. 125  
 Liberati AM, Ballatori E, Fizzotti M, Schippa M, Cini L, Cinieri S, Proietti MG, Di Marzio R, Senatore M, Grignani F: A randomized trial to evaluate the immuno restorative properties of thyrotropin in patients with Hodgkin's disease in complete remission 87  
 Liebert M → Wahl RL, et al. 187  
 Liu D → Steele JK, et al. 125  
 Los G, De Weger RA, Van den Berg DTWM, Sakkers R, Den Otter W: Macrophage infiltration in tumors and tumor-surrounding tissue: influence of serotonin and sensitized lymphocytes 145  
 Mage MG → Romani L, et al. 48  
 Marquet RL → Eggermont AMM, et al. 23  
 Martin A → Collet B, et al. 237  
 Masuno T → Yokota S, et al. 11  
 Matsui Y → Okamoto Y, et al. 176  
 Matsuzaki T, Yokokura T, Mutai M: Antitumor effect of intrapleural administration of *Lactobacillus casei* in mice 209  
 Mazzocchi A → Taramelli D, et al. 61  
 McIntosh J → Mulé JJ, et al. 202  
 Meadows GG, Abdallah RM, Starkey JR, Aslakson CJ: Response of natural killer cells from dietary tyrosine- and phenylalanine-restricted mice to biological response modifiers 67  
 Mezzananza D → Orlandi R, et al. 114  
 Minato K → Sakurai M, et al. 109  
 Minkoff DZ → Kohler PC, et al. 74  
 Miyao Y → Okamoto Y, et al. 176  
 Mogami H → Okamoto Y, et al. 176  
 Moisan A → Collet B, et al. 237  
 Möller-Larsen A → Bukh A, et al. 280  
 Möller-Larsen F → Bukh A, et al. 280  
 Möller NPH → Bukh A, et al. 280  
 Morikage T → Hosokawa M, et al. 250  
 Morikawa K, Hamada J, Itaya T, Ishikawa M, Takeichi N, Hosokawa M, Kobayashi H: Modification of regression of virally xenogenized tumor cells by cyclophosphamide and busulfan 18  
 Morikawa K → Hosokawa M, et al. 250  
 Mulé JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA: Transforming growth factor beta inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells 95  
 Mulé JJ, Asher A, McIntosh J, Lafreniere R, Shiloni E, Lefor A, Reichert CM, Rosenberg SA: Antitumor effect of recombinant tumor necrosis factor- $\alpha$  against murine sarcomas at visceral sites: tumor size influences the response to therapy 202  
 Mutai M → Matsuzaki T, et al. 209  
 Mutai M → Kato I, et al. 215  
 Nakagawa K → Sakurai M, et al. 109  
 Nakajima H → Shima J, et al. 43  
 Nakano H → Sakurai M, et al. 109  
 Nishikawa H → Yokota S, et al. 11  
 North RJ → Awwad M 55  
 Ogura T → Yokota S, et al. 11  
 Ohe Y → Sakurai M, et al. 109  
 Okada F → Hosokawa M, et al. 250  
 Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Tsuda N, Matsui Y, Mogami H: Effects of phenytoin on cell-mediated immunity 176  
 Olsson N-O → Pelletier H, et al. 263  
 Orlandi R, Canevari S, Conde FP, Leoni F, Mezzananza D, Ripamonti M, Colnaghi MI: Immunconjugate generation between the ribosome inactivating protein restriction and an anti-human breast carcinoma MAB 114  
 Osawa T → Shimoda O, et al. 101  
 Otsu A → Sakurai M, et al. 109  
 Ottesen SS, Tromholt V, Kieler J: Correlation between classification of human urothelial cell lines and HLA-A,B,C expression 83  
 Parmiani G → Taramelli D, et al. 61  
 Pellen P → Collet B, et al. 237  
 Pelletier H, Olsson N-O, Fady C, Reisser D, Lagadec P, Jeannin J-F: Differential sensitivity to natural cell-mediated cytotoxicity of two rat colon adenocarcinoma variants differing in their tumorigenicity: identification of the effector cells as natural killer cells 263  
 Pession A → Tazzari PL, et al. 231  
 Pestka S → Guadagni F, et al. 222  
 Pothen S → Guadagni F, et al. 222  
 Proietti MG → Liberati AM, et al. 87  
 Puccetti P → Romani L, et al. 48  
 Ramsdell FJ, Shau H, Golub SH: Role of proliferation in LAK cell development 139  
 Rees RC → Wing MG, et al. 161  
 Rees RC → Wing MG, et al. 169  
 Reichert CM → Mulé JJ, et al. 202  
 Reisser D → Pelletier H, et al. 263  
 Reuben C, Halperin D, Ben-Efraim S, Weiss DW: Induction by an immunogenic immunomodulating agent of nonspecific T cell suppression of lymphocyte responsiveness in MLR but not of antibody production 153  
 Rhijnsburger EH → Berends D, et al. 243  
 Ripamonti M → Orlandi R, et al. 114  
 Rizzi S → Tazzari PL, et al. 231  
 Roberts AB → Mulé JJ, et al. 95  
 Rogers K → Wing MG, et al. 161  
 Rogers K → Wing MG, et al. 169  
 Romani L, Grohmann U, Fazioli F, Puccetti P, Mage MG, Fioretti MC: Cell-mediated immunity to chemically xenogenized tumors. I. Inhibition by specific antisera and H-2 association of the novel antigens 48  
 Rosenberg SA → Mulé JJ, et al. 95  
 Rosenberg SA → Mulé JJ, et al. 202  
 Saito N → Sakurai M, et al. 109  
 Sakkers R → Los G, et al. 145  
 Sakurai M, Iigo M, Tamura T, Otsu A, Sasaki Y, Nakano H, Nakagawa K, Minato K, Ohe Y, Saito N: Comparative study of the anti-tumor effect of two types of murine recombinant interferons, ( $\beta$ ) and ( $\gamma$ ), against B16-F10 melanoma 109  
 Sasaki Y → Sakurai M, et al. 109  
 Sawamura Y → Hosokawa M, et al. 250  
 Schippa M → Liberati AM, et al. 87  
 Schlom J → Guadagni F, et al. 222  
 Schwarz SL → Mulé JJ, et al. 95  
 Senatore M → Liberati AM, et al. 87  
 Shau H → Ramsdell FJ, et al. 139  
 Shiloni E → Mulé JJ, et al. 202

Shimada S → Shimoda O, et al. 101  
 Shima J, Yoshioka T, Nakajima H, Fujiwara H, Hamaoka T: The augmentation of tumor-specific immunity using haptenic muramyl dipeptide (MDP) derivatives. III. Eradication of disseminated murine chronic leukemic cells by utilizing MDP haptene-reactive helper T-cell activity 43  
 Shimizu K → Okamoto Y, et al. 176  
 Shimoda O, Takeda Y, Woo HJ, Shimada S, Higuchi M, Osawa T: A human macrophage hybridoma producing a cytotoxic factor distinct from TNF, LT, and IL-1 101  
 Shirasaka T → Yokota S, et al. 11  
 Shultz LD → Evans R, et al. 35  
 Smith HS → Bjorn MJ, et al. 121  
 Sondel PM → Kohler PC, et al. 74  
 Sporn MB → Mulé JJ, et al. 95  
 Stammers AT → Steele JK, et al. 125  
 Starkey JR → Meadows GG, et al. 67  
 Steele JK, Liu D, Stammers AT, Whitney S, Levy JG: Suppressor deletion therapy: selective elimination of T suppressor cells in vivo using a hematoporphyrin conjugated monoclonal antibody permits animals to reject syngeneic tumor cells 125  
 Stein J → Grossmann HB, et al. 269  
 Stirpe F → Tazzari PL, et al. 231  
 Sugarbaker PH → Eggermont AMM, et al. 23  
 Takagi S → Whiteside TL, et al. 1  
 Takeda Y → Shimoda O, et al. 101  
 Takeichi N → Morikawa K, et al. 18  
 Tamura K → Okamoto Y, et al. 176  
 Tamura T → Sakurai M, et al. 109  
 Taramelli D, Mazzocchi A, Clemente C, Fossati G, Parmiani G: Lack of suppressive activity of human primary melanoma cells on the activation of autologous lymphocytes 61  
 Tazzari PL, Barbieri L, Gobbi M, Dinota A, Rizzi S, Bontadini A, Pession A, Tura S, Stirpe F: An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells 231  
 Toujas L → Collet B, et al. 237  
 Tromholt V → Ottesen SS, et al. 83  
 Tsuda N → Okamoto Y, et al. 176  
 Tura S → Tazzari PL, et al. 231  
 Unsgaard G → Helseth E, et al. 273  
 Van den Berg DTWM → Los G, et al. 145  
 Vik R → Helseth E, et al. 273  
 Volk MJ → Hadar EJ, et al. 31  
 Wagner JG → Wahl RL, et al. 187  
 Wahl RL, Barrett J, Geatti O, Liebert M, Wilson BS, Fisher S, Wagner JG: The intraperitoneal delivery of radiolabeled monoclonal antibodies: studies on the regional delivery advantage 187  
 Wedemeyer G → Grossmann HB, et al. 269  
 Weiss DW → Reuben C, et al. 153  
 Wei W-Z, Heppner GH: Tumor infiltrating lymphocytes of spontaneous versus transplanted mouse mammary tumors 257  
 Whiteside TL, Heo DS, Takagi S, Johnson JT, Iwatsuki S, Herberman RB: Cytolytic antitumor effector cells in long-term cultures of human tumor-infiltrating lymphocytes in recombinant interleukin 2 1  
 Whitney S → Steele JK, et al. 125  
 Wilson BS → Wahl RL, et al. 187  
 Wing MG, Goepel JR, Jacob G, Rees RC, Rogers K: Comparison of excision versus cryosurgery of an HSV-2-induced fibrosarcoma. I. Survival, extent of metastatic disease and host immunocompetence following surgery 161  
 Wing MG, Rogers K, Jacob G, Rees RC: Characterisation of suppressor cells generated following cryosurgery of an HSV-2-induced fibrosarcoma 169  
 Woo HJ → Shimoda O, et al. 101  
 Xu Z-Y → Hosokawa M, et al. 250  
 Yamada M → Okamoto Y, et al. 176  
 Yokokura T → Matsuzaki T, et al. 209  
 Yokokura T → Kato I, et al. 215  
 Yokota S, Shirasaka T, Nishikawa H, Hosoe S, Ikeda T, Komuta K, Kawase I, Masuno T, Ogura T, Kishimoto S: Augmentative effect of *Nocardia rubra* cell-wall skeleton (N-CWS) on lymphokine-activated killer (LAK) cell induction 11  
 Yoshioka T → Shima J, et al. 43

Indexed in *Current Contents*

## Subject index of volume 26

- ABPP 23
- Angiogenesis 31
- Antibody
  - ADCC 18
  - autologous 269
  - monoclonal 114, 125, 187, 222, 231, 237, 243
  - scintigraphy 237
- Antigen
  - CEA 180
  - HLA 74, 83
  - Ia 215
  - Mac-1 237
- Autologous reactivity 269
- Bladder cancer 269
- Blastogenesis assays 169
- Biological response modifiers 67
- Brain neoplasm 176
- Brain tumors 273
- Breast cancer 114, 121, 180, 257
- Busulfan 18
- Chemoimmunotherapy 74, 132
- Clonal assays 121
- Colon carcinoma 263
- Colorectal cancer 180
- Cryosurgery 161, 169
- Cyclophosphamide 18, 250
- Cytotoxicity
  - effector cells 35
  - factor 101
  - T cells 95
- Diet
  - NK cells 67
- Gliomas 273
- Growth factor
  - TGF-beta 273
- Hematoporphyrin 125
- HLA 74, 83
- Hodgkin's disease 87
- Immune complexes 180, 280
- Immunity
  - cell mediated 48
  - senescence 31
- Immunocomjugate 114
- Immunomodulating agent 153
- Immunorestitution
  - thymostimulin 87
- Immunosuppression 153
- Immunotherapy 55
  - adoptive 35
  - regional 209
  - tumor-specific 43
- Immunotoxins 121, 231
- Interferon
  - alpha 222
- beta 109
- gamma 109
- Interleukin 2 1, 11, 23, 176, 250
- Lactobacillus casei 209, 215
- LAK cells 11, 23, 95, 139, 250
- Leukemia
  - friend leukemia virus 18
  - L1210 132
- Lymphocytes
  - graft versus host reaction 74
  - MLR 153
  - T 231
- tumor infiltrating 1, 257
- Lymphoid infiltration 1, 145
- Lymphokines 31
  - activated 61
- Macrophage 215
  - human macrophage hybridoma 101
  - tumor 145
- Melanoma 61, 280
  - B16-F10 109
- Metastasis 161
- Meth A 209, 215
- Monoclonal antibody 114, 125, 187, 222, 231, 237, 243
- Muramyl dipeptide 43
- NK cells 67, 161, 263
- Nocardia rubra cell-wall skeleton 11
- Phenytoin 176
- Radiation 55
- Saporin 6 231
- Sarcoma
  - Meth A 209, 215
  - murine 202
- Scintigraphy 237
- Serotonin 145
- Suppressor cells 125, 169
- T cells 153
  - cytotoxic 95
  - helper 43
  - suppressor 125
  - T-T interactions 43
- Thymostimulin 87
- Tumor
  - infiltrates 237, 257
  - 3LL 250
  - macrophage 145, 237
  - necrosis factor 202
  - targeting 187, 243
  - xenogenized 48
- Urothelial cell lines
  - HLA expression 83

